Post by Novo Nordisk

We have just announced that etavopivat is the first oral therapy in phase 3 to both significantly improve haemoglobin and reduce vaso-occlusive crisis events in sickle cell disease.   We have a long‑term commitment to the sickle cell disease community, grounded in working alongside people living with the disease. Together, we are focused on reframing sickle cell disease as the chronic, progressive, and life‑threatening condition it is, with the goal of helping transform outcomes for patients and their communities.   Read more in the company announcement here: https://lnkd.in/dsDYSpPJ #PRESS